MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 516,900 shares, an increase of 490.7% from the April 30th total of 87,500 shares. Approximately 5.2% of the shares of the stock are short sold. Based […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 516,900 shares, an increase of 490.7% from the April 30th total of 87,500 shares. Based on an average daily volume of 183,900 shares, […]
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) and SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Valuation & Earnings This table compares MiNK Therapeutics […]
NEW YORK, May 22, 2024 MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Valuation and Earnings This table compares SpringWorks Therapeutics […]